Canada - English - Health Canada

apotex inc - travoprost - solution - 0.003% - travoprost 0.003% - prostaglandin analogs

Canada - English - Health Canada

teva canada limited - travoprost - solution - 0.004% - travoprost 0.004% - prostaglandin analogs

Canada - English - Health Canada

sandoz canada incorporated - travoprost - solution - 0.004% - travoprost 0.004% - prostaglandin analogs

Canada - English - Health Canada

apotex inc - travoprost - solution - 0.004% - travoprost 0.004% - prostaglandin analogs

Canada - English - Health Canada

mylan pharmaceuticals ulc - travoprost - solution - 0.004% - travoprost 0.004% - prostaglandin analogs

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - travoprost (unii: wj68r08kx9) (travoprost - unii:wj68r08kx9) - travoprost 0.04 mg in 1 ml - travatan z® (travoprost ophthalmic solution) 0.004% is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. none pregnancy category c teratogenic effects: travoprost was teratogenic in rats, at an intravenous (iv) dose up to 10 mcg/kg/day (250 times the maximal recommended human ocular dose (mrhod), evidenced by an increase in the incidence of skeletal malformations as well as external and visceral malformations, such as fused sternebrae, domed head and hydrocephaly. travoprost was not teratogenic in rats at iv doses up to 3 mcg/kg/day (75 times the mrhod), or in mice at subcutaneous doses up to 1 mcg/kg/day (25 times the mrhod). travoprost produced an increase in post-implantation losses and a decrease in fetal viability in rats at iv doses > 3 mcg/kg/day (75 times the mrhod) and in mice at subcutaneous doses > 0.3 mcg/kg/day (7.5 times the mrhod). in the offspring of female rats that received travoprost subcutaneously from day 7 of preg

United States - English - NLM (National Library of Medicine)

alcon laboratories, inc - travoprost (unii: wj68r08kx9) (travoprost - unii:wj68r08kx9) - travoprost 0.04 mg in 1 ml - travatan z® (travoprost ophthalmic solution) 0.004% is indicated for the reduction of elevated intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension. none. risk summary there are no adequate and well-controlled studies in pregnant women to inform a drug-associated risk. in animal reproduction studies, subcutaneous (sc) administration of travoprost to pregnant mice and rats throughout the period of organogenesis produced embryo-fetal lethality, spontaneous abortion, and premature delivery at potentially clinically relevant doses. advise pregnant women of a potential risk to a fetus. because animal reproductive studies are not always predictive of human response, travatan z should be administered during pregnancy only if the potential benefit justifies the potential risk to the fetus. the background risk of major birth defects and miscarriage for the indicated population is unknown; however, in the u.s. general population, the estimated background risk of major birth defects is

European Union - English - EMA (European Medicines Agency)

novartis europharm limited - travoprost, timolol - glaucoma, open-angle; ocular hypertension - ophthalmologicals - decrease of intraocular pressure (iop) in adult patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.

European Union - English - EMA (European Medicines Agency)

novartis europharm limited - travoprost - ocular hypertension; glaucoma, open-angle - ophthalmologicals, antiglaucoma preparations and miotics - decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1). decrease of elevated intraocular pressure in paediatric patients aged 3 years to < 18 years with ocular hypertension or paediatric glaucoma.